|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
From the Blogosphere
Masimo’s New Product – Analyst Blog
|
|
|
<>
Masimo Corporation (MASI) recently received the U.S. Food and Drug Administration (FDA) approval for its new product, Masimo Rainbow SET Acoustic Monitoring. The new product enables noninvasive and continuous monitoring of human respiration rate (RRa). The data provided is accurate, easy-to-use, and thereby enhances patient compliance. With the approval, Masimo expects to launch the product in a limited market release in the U.S. in this month.
The new product enables earlier detection of respiratory compromise and patient distress. This is especially important for post-surgical patient...
|
Advocate Renews Deal with Masimo – Analyst Blog
|
|
|
<>
Masimo Corporation (MASI) announced that one of its prominent customers, Advocate Health Care, has recently renewed its multi-year, system-wide contract for Masimo SET pulse oximetry technology. Advocate Health Care is Illinois' largest and one of the top ten health care providers in the U.S. It has more than 200 patient-care sites across Chicago. Financial terms of the contract have not been disclosed.
Advocate Health Care has been Masimo’s customer since 2001. The contract enables Masimo to support the pulse oximetry needs of more than 200 sites of Advocate Health Care. This will in t< />< />< /><><><><><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
CFN Enters Agreement with Masimo – Analyst Blog
|
|
|
CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development.
The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise.
CareFusion’s ventilators < />< /><><>< />< />< />< /><><><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
Masimo Beats Zacks Estimate – Analyst Blog
|
|
|
Masimo Corporation (MASI) reported third quarter fiscal 2009 results. Earnings per share were 22 cents, beating the Zacks Consensus Estimate of 21 cents. However, earnings were flat year over year.
Total revenues in the reported quarter increased roughly 12% year over year to $87.4 million. Product revenues increased 14% year over year to $75.1 million. Royalty revenues increased roughly 2% year over year to $12.3 million. Growth in product revenue can be attributed to higher demand for Masimo SET and Masimo Rainbow SET monitors.
Masimo SET revenues increased approximately 10% year over y...
|
Haemonetics Reports Strong Results – Analyst Blog
|
|
|
Haemonetics Corporation (HAE) reported strong results for the second quarter of fiscal 2010. Earnings per share were 69 cents, beating the Zacks Consensus Estimate of 65 cents and the year-ago earnings of 58 cents.
Sales
Total revenues in the reported quarter were $157 million, increasing 8% year over year. Excluding a favorable foreign currency translation (FX), revenues increased 6% year over year. On a geographic basis, U.S. sales represented roughly 48% of total sales and increased 12.5% year over year. International sales increased 3.5% year over year.
Plasma disposables revenues increase...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Haemonetics Corp
- Answers.com
